Does Rallies show 13F holders for FDMT?

Yes. Rallies tracks hedge fund and 13F ownership data for FDMT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is FDMT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FDMT. It does not provide personalized investment advice.

FDMT (4D Molecular Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of May 21, 2026, FDMT trades at $8.47 with a market cap of $437.29M and a P/E ratio of -3.28. FDMT moved +0.89% today. Year to date, FDMT is +16.03%; over the trailing twelve months it is +120.00%. Its 52-week range spans $2.24 to $12.34. Analyst consensus is strong buy with an average price target of $29.00. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns FDMT stock?

Hedge funds tracked by Rallies that own FDMT include Viking Global, Redmile Group, Soros Fund, and Panagora Asset. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for 4D Molecular Therapeutics, Inc. Common Stock.

FDMT Key Metrics

Key financial metrics for FDMT
Metric	Value
Price	$8.47
Market Cap	$437.29M
P/E Ratio	-3.28
EPS	$-2.57
Dividend Yield	0.00%
52-Week High	$12.34
52-Week Low	$2.24
Volume	0
Avg Volume	0
Revenue (TTM)	$88.24M
Net Income	$-160.90M
Gross Margin	0.00%

Top Hedge Funds Holding FDMT

Viking Global holds 2.93M shares of FDMT, changed +0.00% as of Jun 30, 2024.
Redmile Group holds 112.17K shares of FDMT, changed -88.75% as of Jun 30, 2025.
Soros Fund holds 62.50K shares of FDMT, changed +0.00% as of Mar 31, 2024.
Panagora Asset holds 47.33K shares of FDMT, changed +0.74% as of Mar 31, 2026.

Latest FDMT News

4D Molecular Therapeutics Reports $458M Cash, Completes 523-Patient Phase 3 Enrollment — May 7, 2026
4D Molecular Therapeutics Posts $0.43 EPS, $85M Q4 Revenue Beat Expectations — Mar 19, 2026
4D Molecular Therapeutics Secures $514M Cash Runway, Otsuka $85M Deal — Mar 18, 2026
4D Molecular Therapeutics Completes Phase 3 Enrollment in 11 Months, Secures $33 Target — Feb 28, 2026
4D Molecular Therapeutics Grants 124,200 RSUs to Nine New Hires — Feb 13, 2026

Recent FDMT Insider Trades

Gupta Ashoo sold 310 (~$2.67K) on Mar 20, 2026.
Gupta Ashoo sold 80 (~$688.8) on Mar 20, 2026.
Gupta Ashoo sold 310 (~$2.69K) on Dec 20, 2025.

FDMT Analyst Consensus

9 analysts cover FDMT: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.00.

Common questions about FDMT

Who owns FDMT stock?: Hedge funds tracked by Rallies that own FDMT include Viking Global, Redmile Group, Soros Fund, and Panagora Asset. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for 4D Molecular Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for FDMT?: Yes. Rallies tracks hedge fund and 13F ownership data for FDMT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is FDMT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FDMT. It does not provide personalized investment advice.